Skip to Content
Merck
All Photos(1)

Documents

T4827

Sigma-Aldrich

Trandolapril

≥98% (HPLC), white, powder

Synonym(s):

(2S,3aR,7aS)-1-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-1H-indole-2-carboxylic acid, Mavik

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C24H34N2O5
CAS Number:
Molecular Weight:
430.54
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

color

white

solubility

DMSO: ≥20 mg/mL

originator

Abbott

SMILES string

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2C3CCCCC3C[C@H]2C(O)=O

InChI

1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1

InChI key

VXFJYXUZANRPDJ-WTNASJBWSA-N

Gene Information

human ... ACE(1636)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Trandolapril has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on responsiveness of human retinal endothelial cells (HRECs) to vascular endothelial growth factor (VEGF).

Biochem/physiol Actions

Studies have reported that trandolapril inhibits atherosclerosis1 and decreases the occurrence of atrial fibrillation2.
Trandolapril is an ACE inhibitor. Trandolapril differs from other ACE inhibitors in that it has a longer biological half-life and a high degree of lipophilicity.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Trandolapril is soluble in DMSO at a concentration that is greater than or equal to 20 mg/ml.

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Repr. 1B

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 2

1 of 2

Lisinopril ≥98% (HPLC)

Sigma-Aldrich

L6292

Lisinopril

Christian Lewinter et al.
European journal of heart failure, 13(12), 1349-1354 (2011-10-27)
Patients with acute myocardial infarction (MI) with bundle branch block (BBB) have a poor prognosis, but distinction between left (L)- and right (R)-sided BBB is seldom made in epidemiological studies. We studied long-term mortality associated with RBBB and LBBB in
Anthony A Bavry et al.
The American journal of medicine, 124(7), 614-620 (2011-05-21)
There is limited information about the safety of chronic nonsteroidal anti-inflammatory drugs (NSAIDs) in hypertensive patients with coronary artery disease. This was a post hoc analysis from the INternational VErapamil Trandolapril STudy (INVEST), which enrolled patients with hypertension and coronary
M Dendeni et al.
International journal of pharmaceutics, 438(1-2), 61-70 (2012-09-11)
Various regulatory authorities like International Conference on Harmonization (ICH), US Food and Drug Administration, Canadian Drug and Health Agency are emphasizing on the purity requirements and the identification of impurities in active pharmaceutical drugs. Qualification of the impurities is the
Michelle L O'Donoghue et al.
Clinical chemistry, 57(9), 1311-1317 (2011-07-26)
Secretory phospholipase A(2) (sPLA(2)) may contribute to atherogenesis. To date, few prospective studies have examined the utility of sPLA(2) for risk stratification in coronary artery disease (CAD). We measured plasma sPLA(2) activity at baseline in 3708 subjects in the PEACE
Piero Ruggenenti et al.
Journal of the American Society of Nephrology : JASN, 23(10), 1717-1724 (2012-09-01)
Micro- or macroalbuminuria is associated with increased cardiovascular risk factors among patients with type 2 diabetes, but whether albuminuria within the normal range predicts long-term cardiovascular risk is unknown. We evaluated the relationships between albuminuria and cardiovascular events in 1208

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service